经皮下与经腺体内注射超声造影剂检测乳腺癌前哨淋巴结的比较  

The Contrast of Ultrasound Contrast Agents Injection Through Percutaneous and Parenchymal in Detection of Sentinel Lymph Nodes in Breast Cancer Patients

作　　者：马丽园[1] 王文[2] 米成嵘[2] 

机构地区：[1] 宁夏医科大学,银川市750004 [2] 宁夏医科大学总医院超声科

出　　处：《中国超声医学杂志》2014年第4期313-316,共4页Chinese Journal of Ultrasound in Medicine

基　　金：宁夏回族自治区2009年科技攻关项目(No.宁科计字2009139);宁夏人事厅2010留学归国人员项目(No.宁人社发2010516)

摘　　要：目的探讨超声造影在检测乳腺癌SLN中最佳造影剂注射部位及其临床价值。方法对55例乳腺癌患者分别经肿块周围皮下及肿块周围腺体内注射超声造影剂(Sono Vue),实时动态观察前哨淋巴结造影增强情况,并与亚甲蓝染色及病理结果对照。结果 55例乳腺癌患者经肿块周围皮下注射超声造影剂SIN检出率为89.09%(49/55),灵敏度91.67%,特异度82.35%,准确度89.23%;经肿块周围腺体内注射SLN检出率为67.27%(37/55),灵敏度83.78%,特异度100%,准确度87.50%。比较经皮下及经腺体内CEUS判断SLN转移与否的灵敏度、特异度和准确度.两者之间差异无统计学意义(P>0.05)。结论经肿块周围皮下注射超声造影剂可以较好的检出S1N并判断其是否转移,具有很好的临床实用价值。Objective To investigate the best injection site of CEUS in identification of the sentinel lymph nodes and clinical application value in breast cancer patients. Methods Ultrasound contrast agents were injected into 55 ca- ses of breast cancer patients through percutaneous and parenchymal of the borderline in breast tumor, respectively. Then observe the results of contrast-enhanced axillary lymph node which compared with the methylene blue staining and pathology. Results SLN were successfully detected through percutaneous injection of ultrasound contrast agents in 49 of 55 patients, the detection rate, sensitivity, specificity and accuracy were 89.09%, 91.67%, 82.3% and 89.23%. By parenchymal injection CEUS, enhanced lymph nodes were detected in 37 patients and its detection rate, sensitivity, specificity and accuracy were 67.27% ,83.78 %, 100% and 87.50%, respectively. There were no statisti- cal differences for the SLN of diagnostic sensitivity, specificity and accuracy after injection of CEUS through percuta- neous and parenchymal of the borderline in breast tumor （P〉0.05）. Conclusions The percutaneous injection of ultra- sound contrast agents could optimized for detect and assess SLN, and have high value for clinical application.

关 键 词：皮下注射 腺体内注射 超声造影 前哨淋巴结 

分 类 号：R737.9[医药卫生—肿瘤]